Head-to-head evidence
CT-P13 vs JNJ-78934804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
CT-P13 · Inflectra / Remsima
Marketed by Celltrion
NCT02096861 · Phase 3 · completed
Randomized, double-blind Phase 3 non-inferiority trial of CT-P13 against originator infliximab in biologic-naive active Crohn's disease (n=220). The primary endpoint, CDAI-70 response at Week 6, met non-inferiority: the lower bound of the 95% CI (-16.9%) was above the -20% margin.
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-P13's landscape · JNJ-78934804's landscape